Pharsight

Troxyca Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685443 PFIZER Sequestering subunit and related compositions and methods
Jul, 2025

(1 year, 17 days from now)

US7815934 PFIZER Sequestering subunit and related compositions and methods
Dec, 2027

(3 years from now)

Troxyca Er is owned by Pfizer.

Troxyca Er contains Naltrexone Hydrochloride; Oxycodone Hydrochloride.

Troxyca Er has a total of 2 drug patents out of which 0 drug patents have expired.

Troxyca Er was authorised for market use on 19 August, 2016.

Troxyca Er is available in capsule, extended release;oral dosage forms.

Troxyca Er can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed.

The generics of Troxyca Er are possible to be released after 12 December, 2027.

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 19, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 August, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

TROXYCA ER family patents

Family Patents